Asra Minerals Limited

ASR

Asra Minerals Ltd. engages in the development and exploration of mineral properties. The company is headquartered in Perth, Western Australia. The firm is focused on developing gold and rare earth elements (REE) and critical minerals projects in Western Australia. The firm's Mt Stirling Project is located near the mining town of Leonora, approximately 240 kilometers (km) north of Kalgoorlie in Western Australia and hosts approximately 10 gold prospects, as well as an inventory of clean heavy rare earth elements and critical minerals. Its Mt Stirling deposit contains five critical REEs: Dysprosium (Dy), Terbium (Tb), Europium (Eu), Neodymium (Nd) and Yttrium (Y). Its Kookynie West project is located approximately 40 km south of its Mt Stirling Gold and REE Project. The firm owns the approximately 172,662-hectare Tarmoola Pastoral Station, which underlies the Company’s gold and REE deposits and infrastructure.

Cogstate Ltd

CGS

Cogstate Ltd. is a global cognitive science company. The company is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimer’s disease and Parkinson’s disease.

Invion Limited

IVX

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for a variety of cancers, atherosclerosis and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The firm is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. The company produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. The company is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).

Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

Magnis Energy Technologies Ltd

MNS

Magnis Energy Technologies Ltd. is engaged in the business of exploring, developing and mining natural flake graphite and manufacturing lithium-ion battey. The company is headquartered in Sydney, New South Wales and currently employs 7 full-time employees. The company went IPO on 2005-10-25. The firm supports and accelerates the adoption of electric vehicles and renewable energy storage critical for the green energy transition. The firm's subsidiary, Imperium3 New York, Inc (iM3NY), operates a Gigawatt scale Lithium-ion battery manufacturing project in Endicott, New York. The company also has a joint venture and lithium-ion research and development (R&D) technology partner, Charge CCCV LLC (C4V). iM3NY has commercialized C4Vs patented cathode chemistry to produce green credentialed lithium-ion battery cells for use in both electric vehicles and battery energy storage systems. The firm also has a 100% interest in the Nachu Project, which is a large-scale natural flake graphite project in Tanzania.